anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Ankle-foot orthoses (AFOs) are commonly prescribed for people with Charcot-Marie-Tooth disease (CMT) to improve gait efficiency and reduce the occurrence of tripping and falls. The aim of this study was to systematically review evidence on the effects of AFOs on gait kinematics and kinetics and postural stability/balance in people with CMT.
METHODS: Studies were identified from electronic databases and screened for inclusion online using Rayyan. Data from all eligible studies were extracted into a standardised Excel spreadsheet. Methodological quality was assessed using the Joanna Briggs Institute Critical Appraisal Checklists. Where available, continuous outcomes were pooled to estimate standardised mean differences in random-effects meta-analyses.
RESULTS: A total of 15 studies were included with variable methodological quality. Sample sizes ranged from 1 to 32 with significant variability in participant characteristics, AFO designs and testing procedures. Data from eight studies were available for meta-analysis. Although AFOs impacted walking velocity, stride length, step length, cadence, ankle dorsiflexion, plantarflexion, knee and hip flexion and ankle plantarflexion and dorsiflexion moments, the effect sizes were small-to-moderate and non-significant. There were insufficient data available for pooled analyses of outcomes related to postural stability/balance.
CONCLUSION: Although AFOs positively affect a number of gait and balance parameters, the small participant numbers, variability in participant characteristics, AFO designs and testing procedures adopted by the available studies resulted in the absence of statistically significant effects when data were pooled. The results from this review also highlight the importance of device customisation based on the individual needs of people with CMT and their degree of gait impairment.
The present invention relates to antiviral compounds selected from cytokinins, their nucleosides and nucleotide analogs, and their prodrugs as inhibitors of viral RNA synthesis, or their salts, solvates, derivatives, or even combinations of aforementioned compounds, for prophylactic treatment, curative (therapeutic) or mitigative coronavirus infection, represented by human and veterinary coronavirus, SARS-CoV-2 and MHV, and for the treatment of individuals potentially exposed to COVID-19. The present invention also comprises the methods for the manufacturing of such compounds, the antiviral pharmaceutical composition containing the compounds of the invention, as well as the use of the compounds, combinations of compounds, and method for the prophylactic, curative (therapeutic) or mitigative treatment of coronavirus infection, represented by coronavirus, in especial SARS-CoV-2 and of patients with COVID-19, individual infected with SARS-CoV-2 or potentially exposed to this virus. The antiviral activity of the compounds of this invention against SARS-CoV-2 was greatly enhanced by inhibiting the 3'-5'-exonuclease. Synergistic results of MB-905, MB-801, MB-711, and MB-804 were obtained with either raltegravir or dolutegravir (acting as inhibitors of exonuclease - iEXO). The one-log (90%) inhibition of viral replication, obtained with the MBs alone, was enhanced to an additional log either by raltegravir or by dolutegravir. Similar synergetic results were observed with sofosbuvir and tenofovir. In contrast, the potency of remdesivir, a delayed-chain terminator, was not increased by iEXO.
Participants will be given matching placebo (0.9% normal saline solution) to use after migraine onset. Participants will put 2 drops of solution in each eye after migraine and then again 2 hours later.
A spore-based probiotic composition is provided that comprises at least one viable probiotic microorganism having a biological or therapeutic effect on microbiome in humans. One exemplary composition contains five different strains of Bacillus spp. Also provided are methods of producing spore-based probiotic compositions. A validated in vitro gut model which is a simulated human intestinal microbial ecosystem reactor was used to assess the long-term effect of the composition on microbial metabolic activity and community composition. The results support use of the composition in protecting against obesity-related disorders, metabolic disorders, inflammation, and cancer, for example. A method for modulating microbial metabolic activity and/or modulating microbial community composition in a human subject is described.
FIELD: biotechnology, immunology, immunobiology. SUBSTANCE: the given stabilizing composition contains protein hydrolysate, saccharose, phosphate-saline buffer, bacteriostatic, bovine serum albumin, EDTA (trilon B) and potassium chloride at the following ratio of components, weight%: bovine serum albumin 0.1-3.0; saccharose 1.0-10.0; protein hydrolysate 1.0-5.0; potassium chloride 2.0-8.0; EDTA (trilon B) 0.03-0.2; bacteriostatic 0.01-0.02; phosphate-saline buffer - the rest. Peptone and gelatin are used as protein hydrolysate and merthiolate is applied as bacteriostatic. Stabilizer provides the safety of biochemical properties of anti-IgG conjugate preparation and horse radish peroxidase during lyophilic drying, subsequent storage and rehydration at the room temperature. EFFECT: higher efficiency to obtain stable types of immunobiological preparations which keep their specific properties for a long period of time. 2 cl, 3 tbl
The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. Clopidogrel can increase the systemic exposure to drugs that are primarily cleared by CYP2C8, thereby needing dose adjustment and appropriate monitoring. 

Clopidogrel increased repaglinide exposures by 3.9-fold to 5.1-fold [see Clinical Pharmacology (12.3)]. Avoid concomitant use of repaglinide with clopidogrel. If concomitant use cannot be avoided, initiate repaglinide at 0.5 mg before each meal and do not exceed a total daily dose of 4 mg. Increased frequency of glucose monitoring may be required during concomitant use.
Depression is a major burden for minority and low-income older adults who are less likely to use mental health services, and development of new service delivery models is needed to improve the quality of life and address disparities to access for this group. The investigators propose to test the effectiveness of a peer-delivered depression care program that is embedded in the community and linked to the patient's primary care clinic. The investigators will carry out a randomized controlled trial of the PEERS program in which peer mentors who have personal experience of depression meet individually with older adults recruited in the community for 8 weekly meetings focused on relief of depressive symptoms through self-care support and linkages to community resources. This group of low-income and minority older adults in the intervention will be compared to a group that receives non-peer visits that provide social interaction. The PEERS program takes a chronic disease self-management approach and is guided by the conceptual frameworks of social support, peer support, and social learning. The investigators will conduct an analysis of mediation to understand the mechanism of peer support, by measuring factors such as self-efficacy and loneliness that may be responsible for the intervention effect. The investigators' goal is to use peer-delivered depression care to decrease the mental health morbidity of at-risk low-income and minority adults. The potential public health impact is high because the investigators' project seeks to increase access to depression for a vulnerable group of older adults who often do not get care and leverages an existing workforce of peer workers whose services are reimbursed in many states.
Imiquimod Cream should be applied 3 times per week to external genital/perianal warts. Imiquimod Cream treatment should continue until there is total clearance of the genital/perianal warts or for a maximum of 16 weeks. Examples of 3 times per week application schedules are: Monday, Wednesday, Friday or Tuesday, Thursday, Saturday. Imiquimod Cream should be applied prior to normal sleeping hours and left on the skin for 6 -10 hours, after which time the cream should be removed by washing the area with mild soap and water. The prescriber should demonstrate the proper application technique to maximize the benefit of Imiquimod Cream therapy. 

It is recommended that patients wash their hands before and after applying Imiquimod Cream. 

A thin layer of Imiquimod Cream should be applied to the wart area and rubbed in until the cream is no longer visible. The application site should not be occluded. Following the treatment period the cream should be removed by washing the treated area with mild soap and water. 

Local skin reactions at the treatment site are common. [see Adverse Reactions (6.3, 6.5)]. A rest period of several days may be taken if required by the patient's discomfort or severity of the local skin reaction. Treatment may resume once the reaction subsides. Non-occlusive dressings such as cotton gauze or cotton underwear may be used in the management of skin reactions. 

Imiquimod Cream is packaged in single-use packets which contain sufficient cream to cover a wart area of up to 20 cm2; use of excessive amounts of cream should be avoided.
BACKGROUND: N-Acetylcysteine (NAC) is a recognized antioxidative agent that facilitates the conjugation of toxic metabolites. In recent years, NAC has been routinely used to limit ischaemia-reperfusion injury in liver transplantation. There remains, however, contradictory evidence on its effectiveness in liver resection. This meta-analysis examines the effectiveness of NAC in improving outcomes following hepatectomy.
METHODS: A comprehensive search of the MEDLINE, EMBASE, and Cochrane databases was performed to identify relevant randomized controlled trials (RCTs) published since database inception until November 2023. The outcomes of Day 1 biochemical markers (lactate, ALT, bilirubin, and INR), length of stay, transfusion rates, and morbidity were extracted. Quantitative pooling of data was based on a random-effects model. The study protocol was registered on PROSPERO (Registration no: CRD42023442429).
RESULTS: Five RCTs reporting on 388 patients undergoing hepatectomy were included in the analysis. There were no significant differences in patient demographics between groups. Post-operative lactate was lower in patients receiving NAC (WMD -0.61, 95% CI -1.19 to -0.04, I2 = 67%). There were, however, no differences in the post-operative INR (WMD -0.04, 95% CI -0.19 to 0.12, I2 = 96%) and ALT (WMD -94.94, 95% CI -228.46 to 40.38; I2 = 67%). More importantly, there were no statistically significant differences in length of stay, transfusion rates, and morbidity between the two groups.
CONCLUSION: The administration of NAC in liver resection did not alter important biochemical parameters suggesting any real effectiveness in reducing hepatic dysfunction. There were no improvements in the clinical outcomes of length of stay, transfusion rates, and overall morbidity.
Glioma represents a primary malignant tumor occurring in the central nervous system. Glutamate decarboxylase (GAD1) plays a significant role in tumor development; however, its function of GAD1 and underlying mechanisms in glioma progression remain unclear. Differentially expressed genes (DEGs) obtained from the GSE12657 and GSE15209 datasets that intersected with cuproptosis-related genes and pivot genes were identified using comprehensive bioinformatics methods. The elesclomol (ES) treatment was used to induce cuproptosis in U251 cells, which was validated by detecting intracellular copper levels and cuproptosis marker expression. Lentivirus-mediated gene overexpression was performed to explore the effects of GAD1 using functional assays in vitro and in a mouse xenograft model. The RAS agonist ML098 was used to verify the effect of GAD1 on the RAS/MAPK pathway in glioma cells. A total of 87 cuproptosis-related DEGs and seven hub genes were obtained, with five genes upregulated and two were downregulated in gliomas. Overexpression of GAD1 inhibited proliferation, invasion, and migration, promoted apoptosis of glioma cells, and suppressed tumorigenesis in vivo. In addition, GAD1 overexpression enhanced the sensitivity of glioma cells to cuproptosis. Additionally, ML098 treatment attenuated the inhibitory effect of GAD1 overexpression on the malignant phenotype of ES-treated cells. GAD1 plays an anti-oncogenic role in glioma by regulating apoptosis via inhibition of the RAS/MAPK pathway.
Novel benzimidazoles of the formula <FORM:1087345/C2/1> wherein R1 represents a hydrogen atom or a C1- 5 alkyl, aralkyl or acyl radical, one of R5 and R6 represent a hydrogen or halogen atom or a C1- 5 alkyl, C1- 5 alkoxy, C1- 5 alkylthio, phenoxy, phenylthio, phenyl or halophenyl radical and the other represents hydrogen and n is 1 or 2, are prepared by reacting a substituted aniline and a substituted furan of the respective formulae <FORM:1087345/C2/2> wherein A represents hydrogen or a nitro group and B represents a carboxy, esterified carboxy or haloformyl radical, to form an amide of the formula <FORM:1087345/C2/3> when A is hydrogen, nitrating this amide to convert A to nitro, and reducing the nitro compound with hydrogen (under certain conditions and when n is 2, the reduction may cause the elimination of one chlorine atom); by reacting the required o-phenylene diamine with the required chloro-substituted-2-furfural, the process being effected in the presence of nitrobenzene benzene or being followed by reaction with an oxidizing agent on the intermediate Schiff type base formed; or by reacting an amidine of the formula <FORM:1087345/C2/4> wherein R5, R6 and n have the above significance (obtainable from the required aniline and required chloro substituted 2-cyano-furan), with a chlorinating or brominating agent to produce the corresponding N-haloamidine and treating this compound with a base.  Ethyl - 2,3,4,5 - tetrachloro - tetrahydrofuran - 2 - carboxylate is prepared by treating ethyl 2-furoate with chlorine, is converted into a mixture of ethyl mono- and poly-chloro-2-furoates by heating the mixture may be separated by fractionally distilling, saponifying the fraction boiling between 123 DEG  and 145 DEG  C. at 20 mm. pressure, forming the calcium salts of the resulting mixture of acids, filtering off the precipitated calcium salts and acidifying the filtrate to precipitate 3,5-dichloro-2-furoic acid or treating an aqueous solution of the said calcium salts with hydrochloric acid and extracting 4,5-dichloro-2-furoic acid.  4 - Chloro - 2 - furoic acid is prepared by the zinc dust-HCl treatment of the corresponding 4,5-dichloro-compound.  4 - Fluoro - 41 - aminobiphenyl is prepared by nitrating 4-fluoro-biphenyl and reducing the resulting 4-fluoro-41-nitrobiphenyl.  Pharmaceutical compositions having anthelmintic activity contain as the active ingredient a compound of the first formula above. The compositions may be in the form of capsules, tablets, boluses, drenches or solutions.
The present invention provides a method for preserving platelets outside a living body. Platelets are the smallest circulating blood cells in human body that have been recently recognized as a link between inflammation and heart diseases, diabetes and cancer. At the site of injury, platelets may adhere, aggregate to help stop bleeding and at the same time may change in shapes to release the stored cell contents from both alpha granules and dense granules to promote tissue regeneration. However, due to their subtle characteristics, platelets have never been succeeded in long-term preservation outside a living body. The present invention is a method that delivers an approach for a long-term in vitro preservation of platelets. This preferred process utilizes a natural biological method to protect membrane of platelets; thereby eliminating the risk of being activation outside a living body. The significances of this process are (1) To deliver a simple and natural way that allows a significant long-term in vitro preservation of platelets than before. (2) To be able to establish in vitro study model, which facilitate further in vitro investigations on the characteristics of platelets.
The present invention relates to a medicine for relieving alcoholism, which is characterized in that No. 33 alpha-hemolytic streptococcus strains are carried by a roundtrip deep space vehicle, DNA double strands in a microbial cell are broken under the special condition of the outer space, and the repair of impaired DNA is inhibited in a microgravity environment and a high vacuum environment, so that the hereditary properties of the NO. 33 alpha-hemolytic streptococcus strains are mutated, and strains with positive mutation and stable hereditary properties are preferably selected, bred and fermented to be produced into a biochemical preparation for relieving alcoholism. The strains are preserved in China General Microbiological Culture Collection Center and have a serial number of CGMCCNO. 1082. The biochemical preparation for relieving alcoholism is oral liquid, and 1000 ml of the biochemical preparation contains 0.8g to 15.0g of mannon peptide produced by using the strains mutated in the outer space. In the medicine for relieving alcoholism, a biochemical preparation is adopted to relieve and prevent alcoholism, and the present invention has the characteristics of no toxin, small side effect and high effective rate.
Management of trauma is a neglected field in developing nations.Road Traffic Injuries (RTI) cause around 1.35 million deaths worldwide annually according to the statistics of World Health Organization (WHO) and in India 150000 death per year. An overwhelming proportion of these deaths occur before patients even reach the hospital. Two third (60.7%) of the accident victims belonged to the age range of 15 to 44 years. This indicates that active and productive age people are the one affected by road traffic accidents related injuries in turn adding to higher economic loss to the country. Lack of medical attention is attributed to nearly 30 per cent of deaths at site and 80 per cent of the remaining patients died within an hour of injury (golden hour). Most of these deaths are due to airway management failure, respiratory failure or continuing hemorrhage that are preventable causes with appropriate prehospital and subsequent hospital emergency care. Mortality due to RTI is increasing, especially in Low and Middle Income Countries (LMIC). There is a lack of research on the effectiveness of pre-hospital care in India. Selection of appropriate strategies and correct policy-making in these conditions may lead to decreased rates of death due to RTI in several countries.This study aimed to describe the prehospital care of RTI victims presenting to the emergency department (ED) in Jubilee Mission Medical College and Research Institute, Thrissur.
<P>PROBLEM TO BE SOLVED: To provide a biological state-related information-providing system which can easily grasp the daily state of the body of a human being, and can easily perform a health management.  <P>SOLUTION: This biological state-related information-providing system 1 is constituted of a biological information-receiving unit 26, an individual database 25, a processing unit 21, and a display unit 22. In this case, the biological information-receiving unit 26 receives the biological information of a member 20 which varies from a biological information-measuring sensor 6. The individual database 25 stores the biological information received by the biological information-receiving unit 26. The processing unit 21 calculates a biological state stabilizing value of the member from the biological information in the past which is stored in the individual database 25, and compares the biological state stabilizing value and the present biological information which is received by the biological information-receiving unit 26. The display unit 22 displays the result which is compared by the processing unit 21.  <P>COPYRIGHT: (C)2003,JPO
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder that affects social skills, language, communication, and behavioral skills, significantly impacting the individual's quality of life. Recently, numerous works have centered on the connections between the immune and central nervous systems and the influence of neuroinflammation on autism symptomatology. Marine natural products are considered as important alternative sources of different types of compounds, including polysaccharides, polyphenols, sterols, carotenoids, terpenoids and, alkaloids. These compounds present anti-inflammatory, neuroprotective and immunomodulatory activities, exhibiting a potential for the treatment of many diseases. Although many studies address the marine compounds in the modulation of inflammatory mediators, there is a gap regarding their use in the regulation of the immune system in ASD. Thus, this review aims to provide a better understanding regarding cytokines, chemokines, growth factors and immune responses in ASD, as well as the potential of bioactive marine compounds in the immune regulation in ASD. We expect that this review would contribute to the development of therapeutic alternatives for controlling immune mediators and inflammation in ASD.
The USP (United States Pharmacopeia Convention) Endotoxin RS (LPS; Endotoxin Reference Standard, Escherichia coli, Pharmacopeia, Rockville, MD, US) will be ordered.and comes as a lyophilized (freeze-dried) powder, and each vial contains 10,000 USP Endotoxin Units. Each vial contains approximately 1 microgram of Endotoxin. The lyophilized LPS will be dissolved in 5mL sterile water to obtain a solution at 200 ng/mL. This solution will be aliquoted in 400μL (thus containing 80ng endotoxin) and stored at -20°C. Aliquots will be sent for microbial safety testing routine and verification of endotoxin concentration to a certified laboratory. On the study day, 2100μL of physiological saline (sterile, pyrogen-free isotonic NaCl solution) will be added to the aliquot to obtain a final concentration of 32 ng/mL. The amount of solution to inject will then be calculated according to the participant's weight \[in mL = (0.8 x weight) / 32\].
MEDI4736 (durvalumab) will be given by IV infusion once every 4 weeks. AZD1775 will be given orally in approximate 12 hour intervals over 3 days (6 doses) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
A qualitative, community-engaged assessment was conducted to identify needs and priorities for infant obesity prevention programs among mothers participating in home visiting programs. Thirty-two stakeholders (i.e., community partners, mothers, home visitors) affiliated with a home visiting program serving low-income families during the prenatal to age three period participated in group level assessment sessions or individual qualitative interviews. Results indicated families face many challenges to obesity prevention particularly in terms of healthy eating. An obesity prevention program can address these challenges by offering realistic feeding options and non-judgmental peer support, improving access to resources, and tailoring program content to individual family needs and preferences. Informational needs, family factors in healthy eating outcomes, and the importance of access and awareness of programs were also noted. To ensure the cultural- and contextual-relevance of infant obesity prevention programs for underserved populations, needs and preferences among community stakeholders and the focal population should be used as a roadmap for intervention development.